Agreement No.: 012008.

Title: The 360 Quality Association Agreement.

Parties: NYKLauritzenCool AB and Seatrade Group NV.

Filing Party: Wayne R. Rohde, Esq.; Sher & Blackwell LLP; 1850 M Street, NW., Suite 900; Washington, DC 20036.

Synopsis: The agreement authorizes the parties to implement, supervise, and administer a code of conduct applicable to the handling of specialized reefer cargoes and to implement, manage, exploit and own any such code and any intellectual property rights associated therewith.

By Order of the Federal Maritime Commission.

Dated: August 3, 2007.

Karen V. Gregory,

Assistant Secretary.

[FR Doc. E7–15437 Filed 8–7–07; 8:45 am]

BILLING CODE 6730–01–P

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisition of Shares of Bank or Bank Holding Companies

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the office of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than August 23, 2007.

A. Federal Reserve Bank of Kansas City (Todd Offenbacker, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198-0001:

1. Emmalie Gessner Cowherd, as an individual, as trustee of the Emmalie Gessner Cowherd Revocable Living Trust, as personal representative of the Clifton R. Cowherd Estate and as a member of a group acting in concert with Benjamin G. Polen; to retain voting shares of Carroll County Bancshares, Inc., and thereby indirectly retain voting shares of Carroll County Trust Company of Carrollton, Missouri, all of Carrollton, Missouri.

Board of Governors of the Federal Reserve System, August 3, 2007.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. E7–15436 Filed 8–7–07; 8:45 am]

BILLING CODE 6210–01–S

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at *www.ffiec.gov/nic/*.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than September 4, 2007.

A. Federal Reserve Bank of Kansas City (Todd Offenbacker, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198-0001:

1. Carroll County Bancshares, Inc., Carrollton, Missouri, to acquire up to 100 percent of the voting shares of Farmers and Merchants Bank, Hale, Missouri.

B. Federal Reserve Bank of San Francisco (Tracy Basinger, Director, Regional and Community Bank Group) 101 Market Street, San Francisco, California 94105-1579:

1. Sterling Financial Corporation, Spokane, Washington; to merge with North Valley Bancorp, and thereby indirectly acquire North Valley Bank, both of Redding, California.

Board of Governors of the Federal Reserve System, August 3, 2007.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. E7–15435 Filed 8–7–07; 8:45 am]

BILLING CODE 6210–01–S

FEDERAL RETIREMENT THRIFT INVESTMENT BOARD

Sunshine Act; Notice of Meeting

TIME AND DATE: 10 a.m. (Eastern Time), August 20, 2007.

PLACE: 4th Floor Conference Room, 1250 H Street, NW., Washington, DC 20005.

STATUS: Open.

MATTERS TO BE CONSIDERED:

1. Approval of the minutes of the July 16, 2007 Board member meeting.
2. Thrift Savings Plan activity report by the Executive Director.
   a. Monthly Participant Activity Report.
   b. Monthly Investment Performance Report.
   c. Legislative Report.
3. MetLife Audit Report.

FOR FURTHER INFORMATION CONTACT: Thomas J. Trabucco, Director, Office of External Affairs, (202) 942–1640.

Dated: August 6, 2007.

Thomas K. Emswiler,

Secretary to the Board, Federal Retirement Thrift Investment Board.

[FR Doc. 07–3875 Filed 8–6–07; 10:40 am]

BILLING CODE 6760–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Cooperative Agreement To Support the National Alliance for Hispanic Health; Notice of Intent To Accept and Consider a Single Source Application; Availability of Funds for Fiscal Year 2007

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its intent to accept and consider a single source application (RFA-FDA–07–006) for the awarding of a Cooperative

Agreement to the National Alliance for Hispanic Health (the Alliance). The purpose of the agreement is to empower consumers to improve their health by providing better consumer health information; ensure that health information available to consumers is clear, informative, and effective; leverage opportunities to eliminate health disparities in subpopulations; respond to the health promotion and disease prevention objectives of the Department of Health and Human Services (HHS) ''Healthy People 2010'' document; and improve health literacy for Hispanic Americans. FDA anticipates providing $ 35,000.00 (direct and indirect costs) in fiscal year (FY) 2007 in support of this project. Subject to the availability of funds and successful performance, two additional years of support up to $35,000.00 per year (direct and indirect) will be available.

DATES: Applications are due August 24, 2007.

FOR FURTHER INFORMATION CONTACT: Gladys M. Bohler, Office of Acquisitions and Grants Services, Food and Drug Administration, 5630 Fishers Lane, rm. 2105, Rockville, MD 20857, 301–827–7168, or e-mail: *gladys.melendez-bohler@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION:

I. Application and Submission Information

In FY 2007, all applications must be received by August 24, 2007. Applications must be received by close of business on the established receipt date. Late applications may be accepted under extreme circumstances beyond the control of the applicant. Applicants not received on time will not be considered for review and will generally be returned to the applicant.

Applications must be submitted electronically through grants.gov. The application must be on SF424 R&R (Research and Related Portable Document Format). Exceptions may be made in unusual circumstances and on a case by case basis. Applicants must download the SF424 (R&R) application forms and 424 (R&R) Application Guide for this funding opportunity through grants.gov at *http://www.grants.gov/Apply*. Please note, only the forms package directly attached to this specific funding opportunity in grants.gov can be used.

If electronic submission is impossible, please contact Gladys M. Bohler, Grants Management Specialist, at 301–827–7168 or by e-mail at *gladys.melendez-bohler@fda.hhs.gov* (See **Agency Contacts**). When submitting applications electronically, provide URL link, and identify any particular software that is required, and identify your organization contact in the event of system problems.

For the grants.gov electronic application process, applicants are required to register with the Central Contractor Registration (CCR) database. This database is a government-wide warehouse of commercial and financial information for all organizations conducting business with the Federal Government.

Registration with CCR is a requirement and is consistent with the government-wide management reform to create a citizen-centered Web presence and build e-gov infrastructures in and across agencies to establish a ''single face to industry.'' The preferred method for completing a registration is through the World Wide Web at *http://www.ccr.gov*. This Web site provides a CCR handbook with detailed information on data you will need prior to beginning the online registration, as well as steps to walk you through the registration process.

In order to access grants.gov, an applicant will be required to register with the Credential Provider. Information about this is available at *https://apply.grants.gov/OrcRegister.* (FDA has verified the Web site address, but we are not responsible for subsequent changes to the Web site after this document publishes in the **Federal Register**.)

II. Agency Contacts

For issues regarding the administrative and financial management aspects of this notice, contact: Gladys M. Bohler by mail: Office of Acquisitions and Grants Services, Food and Drug Administration, 5630 Fishers Lane, Rockville, MD 20857; telephone: 301–827–7168; FAX: 301–827–7101; e-mail: *gladys.melendez-bohler@fda.gov*.

For issues regarding the programmatic aspects, contact: Mary C. Hitch, Senior Policy Advisor, Office of External Relations (HF–10), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857; telephone: 301–827–4406; FAX: 301–827–8030; e-mail: *mary.hitch@fda.hhs.gov*.

Dated: August 2, 2007.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. E7–15491 Filed 8–7–07; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2006P–0445]

Determination That MIVACRON (Mivacurium Chloride) Injection Equivalent to 2 Milligrams Base/Milliliter Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined that MIVACRON (mivacurium chloride) injection equivalent to (EQ) 2 milligrams (mg) base/milliliter (mL) was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for mivacurium chloride injection EQ 2 mg base/mL.

FOR FURTHER INFORMATION CONTACT: Christine F. Rogers, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98–417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products approved under an ANDA procedure. ANDA applicants must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength and dosage form as the ''listed drug,'' which is a version of the drug that was previously approved. ANDA applicants do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA). The only clinical data required in an ANDA are data to show that the drug that is the subject of the ANDA is bioequivalent to the listed drug.

The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(j)(7)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the ''Approved Drug Products With Therapeutic Equivalence Evaluations'' which is generally known as the ''Orange Book.'' Under FDA regulations, drugs are removed from the list if the agency withdraws or suspends approval